|
NIOSH
Pocket Guide
|
Acrylonitrile |
CAS 107-13-1 |
|
CH2=CHCN |
RTECS AT5250000 |
Synonyms & Trade Names
Acrylonitrile monomer, AN, Cyanoethylene, Propenenitrile, 2-Propenenitrile,
VCN, Vinyl cyanide |
DOT ID & Guide
1093 131P (inhibited) |
Exposure
Limits |
NIOSH REL: Ca TWA 1 ppm C 10 ppm
[15-minute] [skin] |
|
OSHA PEL: [1910.1045] TWA 2 ppm C 10 ppm
[15-minute] [skin] |
|
IDLH Ca [85 ppm] |
Conversion 1 ppm = 2.17 mg/m3
|
Physical Description
Colorless to pale-yellow liquid with an unpleasant odor. [Note:
Odor can only be detected above the PEL.] |
MW: 53.1
|
BP: 171°F
|
FRZ: -116°F
|
Sol: 7%
|
VP: 83 mmHg
|
IP: 10.91 eV
|
|
Sp.Gr: 0.81
|
Fl.P: 30°F
|
UEL: 17%
|
LEL: 3.0%
|
|
|
Class IB Flammable Liquid: Fl.P. below
73°F and BP at or above 100°F. |
Incompatibilities & Reactivities
Strong oxidizers, acids & alkalis; bromine; amines [Note: Unless
inhibited (usually with methylhydroquinone), may polymerize
spontaneously or when heated or in presence of strong alkali.
Attacks copper.] |
Personal Protection & Sanitation
Skin: Prevent skin contact
Eyes: Prevent eye contact
Wash skin: When contaminated
Remove: When wet (flammable)
Change: No recommendation
Provide: Eyewash, Quick drench
|
First Aid
Eye: Irrigate immediately
Skin: Water wash immediately
Breathing: Respiratory support
Swallow: Medical attention immediately
|
Respirator Recommendations NIOSH
At concentrations above the NIOSH REL, or where there is no
REL, at any detectable concentration: (APF = 10,000) Any
self-contained breathing apparatus that has a full facepiece and is
operated in a pressure-demand or other positive-pressure mode/(APF =
10,000) Any supplied-air respirator that has a full facepiece and is
operated in a pressure-demand or other positive-pressure mode in
combination with an auxiliary self-contained positive-pressure
breathing apparatus
Escape: (APF = 50) Any air-purifying, full-facepiece
respirator (gas mask) with a chin-style, front- or back-mounted
organic vapor canister/Any appropriate escape-type, self-contained
breathing apparatus |
|
Exposure Routes inhalation, skin
absorption, ingestion, skin and/or eye contact |
|
Symptoms Irritation eyes, skin;
asphyxia; headache; sneezing; nausea, vomiting; lassitude (weakness,
exhaustion), dizziness; skin vesiculation; scaling dermatitis; [potential
occupational carcinogen] |
Target Organs Eyes, skin,
cardiovascular system, liver, kidneys, central nervous system
Cancer Site [brain tumors, lung & bowel cancer] |
|
